BioSig Technologies Confirms NASDAQ Listing & Corporate Info
Ticker: STEX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $35,000,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, compliance
TL;DR
**BioSig Technologies' 8-K is a routine update confirming its NASDAQ listing, no major news.**
AI Summary
BioSig Technologies, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing is a routine update to confirm the company's registration details, including its common stock trading on The NASDAQ Capital Market under the symbol BSGM. For investors, this filing primarily serves as a confirmation of the company's current public trading status and corporate information, indicating no immediate material changes that would drastically alter investment decisions.
Why It Matters
This filing confirms BioSig Technologies' continued listing on The NASDAQ Capital Market, which is crucial for liquidity and investor confidence. It assures investors that the company remains compliant with exchange requirements.
Risk Assessment
Risk Level: low — This 8-K filing is purely informational, confirming existing details, and does not introduce new risks or material changes to the company's operations or financial standing.
Analyst Insight
A smart investor would note this as a routine compliance filing, confirming the company's operational status on NASDAQ, but would not expect any immediate market reaction or change in investment thesis based solely on this information.
Key Numbers
- $0.001 — Par value per share (The par value of BioSig Technologies, Inc.'s common stock.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — the registrant filing the 8-K
- The NASDAQ Capital Market (company) — the exchange where BioSig's common stock is registered
- BSGM (company) — the trading symbol for BioSig Technologies' common stock
- January 5, 2024 (date) — date of the earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
- $0.001 (dollar_amount) — par value per share of common stock
FAQ
What is the purpose of this 8-K filing by BioSig Technologies, Inc.?
This 8-K filing, dated January 8, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily serving to confirm the company's registration details and its common stock listing on The NASDAQ Capital Market.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024.
What is the trading symbol and exchange for BioSig Technologies, Inc.'s common stock?
BioSig Technologies, Inc.'s common stock trades under the symbol BSGM on The NASDAQ Capital Market.
What is the par value per share of BioSig Technologies, Inc.'s common stock?
The common stock of BioSig Technologies, Inc. has a par value of $0.001 per share.
Is BioSig Technologies, Inc. considered an emerging growth company according to this filing?
The filing includes a checkbox section to indicate if the registrant is an emerging growth company, but none of the boxes are checked, implying the filing does not explicitly state whether BioSig Technologies, Inc. is an emerging growth company.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-01-08 11:00:29
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $35,000,000 — ompany did not meet the minimum MVLS of $35,000,000 required for continued listing on The N
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-001677.txt ( ) — 205KB
- bsgm-20240105.xsd (EX-101.SCH) — 3KB
- bsgm-20240105_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240105_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: January 8, 2024 By: /s/ Kenneth L. Londoner Name: Kenneth L. Londoner Title: Executive Chairman